JP5465667B2 - 抗ウイルス化合物 - Google Patents

抗ウイルス化合物 Download PDF

Info

Publication number
JP5465667B2
JP5465667B2 JP2010514802A JP2010514802A JP5465667B2 JP 5465667 B2 JP5465667 B2 JP 5465667B2 JP 2010514802 A JP2010514802 A JP 2010514802A JP 2010514802 A JP2010514802 A JP 2010514802A JP 5465667 B2 JP5465667 B2 JP 5465667B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
alkoxy
compound
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010514802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532352A (ja
JP2010532352A5 (enExample
Inventor
ジェロミー ジェイ. コーテル,
ジョン オー. リンク,
スコット ディー. シュローダー,
ジェイムス タイラー,
ウィンストン シー. ツェー,
ランダール ダブリュー. ビビアン,
チェン−ユー ヤン,
Original Assignee
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ, インコーポレイテッド filed Critical ギリアード サイエンシーズ, インコーポレイテッド
Publication of JP2010532352A publication Critical patent/JP2010532352A/ja
Publication of JP2010532352A5 publication Critical patent/JP2010532352A5/ja
Application granted granted Critical
Publication of JP5465667B2 publication Critical patent/JP5465667B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010514802A 2007-06-29 2008-06-26 抗ウイルス化合物 Expired - Fee Related JP5465667B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93775207P 2007-06-29 2007-06-29
US60/937,752 2007-06-29
US95969807P 2007-07-16 2007-07-16
US60/959,698 2007-07-16
PCT/US2008/007928 WO2009005677A2 (en) 2007-06-29 2008-06-26 Antiviral compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013124380A Division JP2013177452A (ja) 2007-06-29 2013-06-13 抗ウイルス化合物

Publications (3)

Publication Number Publication Date
JP2010532352A JP2010532352A (ja) 2010-10-07
JP2010532352A5 JP2010532352A5 (enExample) 2011-10-27
JP5465667B2 true JP5465667B2 (ja) 2014-04-09

Family

ID=40202103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010514802A Expired - Fee Related JP5465667B2 (ja) 2007-06-29 2008-06-26 抗ウイルス化合物
JP2013124380A Withdrawn JP2013177452A (ja) 2007-06-29 2013-06-13 抗ウイルス化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013124380A Withdrawn JP2013177452A (ja) 2007-06-29 2013-06-13 抗ウイルス化合物

Country Status (19)

Country Link
US (2) US8513186B2 (enExample)
EP (1) EP2162432A2 (enExample)
JP (2) JP5465667B2 (enExample)
KR (1) KR20100038417A (enExample)
CN (1) CN101801925A (enExample)
AP (1) AP2009005073A0 (enExample)
AR (1) AR068794A1 (enExample)
AU (1) AU2008271117B2 (enExample)
BR (1) BRPI0813733A2 (enExample)
CA (1) CA2692145C (enExample)
CO (1) CO6251241A2 (enExample)
EA (1) EA200971074A1 (enExample)
EC (1) ECSP109906A (enExample)
IL (1) IL202623A0 (enExample)
MX (1) MX2009013830A (enExample)
SG (1) SG182979A1 (enExample)
TW (1) TW200914013A (enExample)
WO (1) WO2009005677A2 (enExample)
ZA (1) ZA201000614B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
ES2437147T3 (es) * 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MY152824A (en) 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
JP2012502925A (ja) * 2008-09-23 2012-02-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎阻害化合物
JP2012512878A (ja) * 2008-12-19 2012-06-07 ギリアード サイエンシーズ, インコーポレイテッド Hcvns3プロテアーゼインヒビター
JP2012516351A (ja) * 2009-01-30 2012-07-19 アナコール ファーマシューティカルズ,インコーポレーテッド 化合物
CA2753657A1 (en) * 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
KR20120026024A (ko) 2009-04-24 2012-03-16 가부시키가이샤 가네카 N-알콕시카르보닐-tert-류신의 제조법
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
BR112012006835A2 (pt) * 2009-09-28 2016-06-07 Hoffmann La Roche inibidores macrocíclicos da replicação do vírus de hepatite c
JP2013505952A (ja) * 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド C型肝炎ウイルス複製の新しい大環状阻害剤
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
CA2780463A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8815881B2 (en) 2010-08-09 2014-08-26 Hoffmann-La Roche Inc. 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
CN103124722B (zh) * 2010-09-22 2014-11-12 三井化学Agro株式会社 具有含氟氨基甲酸酯基的氨基酸酰胺衍生物的制造方法、其制造中间体、及乙二胺衍生物的制造方法
WO2012047764A1 (en) * 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
JP2014502620A (ja) * 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状c型肝炎セリンプロテアーゼ阻害剤
US8951964B2 (en) * 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
PH12014500557A1 (en) 2011-09-16 2014-05-26 Gilead Pharmasset Llc Methods for treating hcv
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
BR112015007887A2 (pt) 2012-10-08 2017-07-04 Abbvie Inc compostos úteis para produzir inibidores hcv protease
JP6154474B2 (ja) * 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102937580B (zh) * 2012-11-02 2015-09-02 天津科技大学 食用油脂中缩水甘油酯的检测方法
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9012441B2 (en) 2013-01-09 2015-04-21 Gilead Sciences, Inc. Therapeutic compounds
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
SG11201508431VA (en) * 2013-03-13 2015-11-27 Harvard College Stapled and stitched polypeptides and uses thereof
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
JP6449274B2 (ja) * 2013-07-11 2019-01-09 エベストラ インコーポレイテッド プロドラッグを生成する化合物
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
CN105504007B (zh) * 2014-10-14 2021-03-16 中国药科大学 氨基磷酸酯衍生物、其制备方法及其在制药中的用途
SMT202100592T1 (it) 2014-12-26 2021-11-12 Univ Emory Derivati antivirali della n4-idrossicitidina
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN118178652A (zh) 2016-05-27 2024-06-14 吉利德科学公司 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
SI3597646T1 (sl) 2016-08-19 2023-10-30 Gilead Sciences, Inc. Terapevtske spojine, uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom hiv
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
BR112020007673A2 (pt) 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
ES2958828T3 (es) 2018-02-15 2024-02-15 Gilead Sciences Inc Derivados de piridina y su uso para tratar una infección por VIH
JP7038843B2 (ja) 2018-02-16 2022-03-18 ギリアード サイエンシーズ, インコーポレイテッド Retroviridaeウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
EP3823621A1 (en) 2018-07-16 2021-05-26 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN111056889B (zh) * 2019-11-22 2022-01-11 华东师范大学 一类n-烷基/n-芳基硫代酰胺衍生物及其合成方法和应用
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
IL300976A (en) * 2020-09-03 2023-04-01 Immunesensor Therapeutics Inc Quinoline compounds as CGAS antagonists
CN112961106A (zh) * 2021-03-13 2021-06-15 德州学院 一种4-羟基-6氯喹啉合成新工艺
US12404262B2 (en) 2021-12-03 2025-09-02 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
HUE072195T2 (hu) 2021-12-03 2025-10-28 Gilead Sciences Inc Terápiás vegyületek HIV-vírusfertõzésre
CA3237155A1 (en) 2021-12-03 2023-06-08 Zhimin Du Therapeutic compounds for hiv virus infection

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998046597A1 (en) 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
DE69829381T2 (de) 1997-08-11 2006-04-13 Boehringer Ingelheim (Canada) Ltd., Laval Hepatitis c inhibitor peptide
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
JP2003525200A (ja) 1998-07-27 2003-08-26 イスティトゥト ディ リチェルケ ディ ビオロジア モレコラーレ ピー.アンジェレッティ ソチエタ ペル アツィオニ ポリメラーゼ阻害剤としてのジケト酸誘導体
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
MXPA01002253A (es) 1998-09-04 2003-06-04 Viropharma Inc Metodo para tratar o prevenir infecciones virales y enfermedades asociadas.
JP2002525295A (ja) 1998-09-25 2002-08-13 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患の治療または予防法
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
IL145071A0 (en) 1999-12-27 2002-06-30 Japan Tobacco Inc Fused ring compounds and pharmaceutical compositions containing the same
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
AU2002248147B2 (en) * 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003248535A1 (en) * 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
EP1505945B1 (en) 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルス阻害剤
CA2515216A1 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
WO2004101602A2 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
EP1601685A1 (en) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
CA2522205A1 (en) * 2003-04-10 2004-10-28 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
ES2320771T3 (es) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
PL1615613T3 (pl) 2003-04-18 2010-04-30 Enanta Pharm Inc Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎ウイルスに対して活性な大環状ペプチド
WO2005095403A2 (en) 2004-03-30 2005-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
PL382845A1 (pl) * 2004-07-16 2008-01-21 Gilead Sciences, Inc. Związki przeciwwirusowe
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
AU2008271117A1 (en) 2009-01-08
ECSP109906A (es) 2010-03-31
JP2010532352A (ja) 2010-10-07
AU2008271117B2 (en) 2013-10-24
EA200971074A1 (ru) 2010-08-30
US20090186869A1 (en) 2009-07-23
IL202623A0 (en) 2010-06-30
CN101801925A (zh) 2010-08-11
AR068794A1 (es) 2009-12-09
US20140051626A1 (en) 2014-02-20
MX2009013830A (es) 2010-03-01
US8809267B2 (en) 2014-08-19
AP2009005073A0 (en) 2009-12-31
KR20100038417A (ko) 2010-04-14
WO2009005677A2 (en) 2009-01-08
ZA201000614B (en) 2011-11-30
US8513186B2 (en) 2013-08-20
SG182979A1 (en) 2012-08-30
WO2009005677A3 (en) 2009-03-05
CA2692145A1 (en) 2009-01-08
TW200914013A (en) 2009-04-01
CA2692145C (en) 2015-03-03
JP2013177452A (ja) 2013-09-09
CO6251241A2 (es) 2011-02-21
BRPI0813733A2 (pt) 2019-11-05
EP2162432A2 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
JP5465667B2 (ja) 抗ウイルス化合物
JP5465666B2 (ja) 抗ウイルス化合物
US20090047252A1 (en) Antiviral compounds
PT2635588E (pt) Imidazolilimidazóis condensados como compostos antivirais
EP2857394A1 (en) Antiviral compounds
AU2014200403B2 (en) Antiviral compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140122

R150 Certificate of patent or registration of utility model

Ref document number: 5465667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees